Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Treatment Approaches in Non-Driver Lung Adenocarcinoma
EP. 1: First-Line Chemotherapy Options in Lung Adenocarcinoma
October 31st 2016
EP. 2: Non-Driver Mutation Non-Squamous NSCLC
October 31st 2016
EP. 3: Potential Upfront and Maintenance Strategies in NSCLC
October 31st 2016
EP. 4: Options in Second-Line Non-Squamous NSCLC
October 31st 2016
EP. 5: PD-L1 Status in Second-Line Lung Adenocarcinoma
October 31st 2016
EP. 6: Non-Driver NSCLC: Clinical Decisions in Rapidly Progressing Disease
October 31st 2016
EP. 7: Differentiating Among Anti-VEGF Therapies in Lung Adenocarcinoma
October 31st 2016
EP. 8: Lung Adenocarcinoma: Patient Selection With Ramucirumab vs Nintedanib
October 31st 2016
EP. 9: Practical Implications of the LUME-Lung 1 Findings
October 31st 2016
EP. 10: Practical Considerations With Nintedanib in Lung Adenocarcinoma
October 31st 2016
NEXT PAGE
<
1
2
>
PREVIOUS PAGE